Pharma major Dr Reddy’s Laboratories Ltd has launched Propofol Injectable Emulsion, a therapeutic equivalent generic version of Diprivan (propofol) Injectable Emulsion, approved by the U.S. Food and Drug Administration (USFDA).
Dr. Reddy’s uses distribution controls to market Propofol Injectable Emulsion and will not accept orders from correctional facilities and prison systems whose intended use of the product is to aid in lethal injection.
The Diprivan brand and generic had US sales of approximately $310 million for the most recent twelve months ending in November 2018 according to IMS Health, according to a release.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.